FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Ark. Code §17-92-401 requires a pharmacy outside Arkansas that routinely ships, mails or delivers dispensed legend drugs into Arkansas to hold a Board pharmacy license and follow Arkansas law for its Arkansas prescriptions. It must have on staff an Arkansas-licensed pharmacist designated pharmacist-in-charge for the Arkansas license and register a resident agent with the Secretary of State. 17 CAR §160-1401 adds that this Arkansas PIC must be an employee present at the pharmacy at least 50% of its open hours, up to 20 hours a week. It also requires a home-state license, a toll-free pharmacist line (40 hours, 6 days a week), retrievable records, and Board inspection, though the Board may accept home-state inspection reports. The Board may exempt pharmacies whose Arkansas dispensing is limited to isolated transactions.

The Board's rules were recodified into the Code of Arkansas Rules (17 CAR Part 160); older sources cite the former 'Regulation 04' numbering. The source documents are titled 'January 2026' (Practice Act) and 'July 2026' (Rules).

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

17 CAR §160-2201(d) requires pharmacies that compound to comply with 'all requirements of Section 503A' of the FD&C Act, which FDA reads as requiring patient-specific prescriptions. The compounding rule allows distribution without a patient-specific prescription only for veterinary office use (§160-2201(i)(4)-(5)). Even then, the product must come from an Arkansas-licensed Class A pharmacy or an FDA-registered, Arkansas-permitted 503B and may not be redistributed. No comparable human office-use provision exists in the rules or the Pharmacy Practice Act. Ark. Code §17-92-121 instead lets an Arkansas-permitted 503B outsourcing facility sell compounded products to Arkansas-licensed providers for administration to patients in a clinic. The Arkansas State Board of Pharmacy enforces.

The rules do not use the word 'prohibited' for human office use. The 'no' answer reflects the 503A-compliance requirement, the veterinary-only office-use provision, and the 503B clinic channel in §17-92-121. Confirm with the Board (501-682-0190).

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

17 CAR §160-2603 requires every outsourcing facility that distributes prescription drugs, including by shipping into Arkansas, to register with the Board for a permit (biennial renewal). 17 CAR §160-2601(8) defines an outsourcing facility as an FDA-registered 503B that is licensed under the wholesale distribution rules as a '503B Outsourcer'. It must have an Arkansas-licensed pharmacist-in-charge on staff at least 32 hours a week and may not provide patient-specific prescriptions unless also licensed as a pharmacy. Ark. Code §17-92-121 limits sales by a Board-permitted 503B to Arkansas-licensed retail pharmacies (for dispensing), health care facilities, and providers (for administration in a clinic). It bars sales to wholesalers, repackagers, relabelers, marketing firms or other entities, and requires cGMP compliance (21 CFR Parts 210-212).

The 32-hour Arkansas-licensed PIC requirement sits in the definition of 'outsourcing facility' in 17 CAR §160-2601(8)(E), which on its face applies to out-of-state 503Bs. 17 CAR §160-2203 governs Arkansas retail pharmacies dispensing 503B products (counseling and extra label items).

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Arkansas is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

The Arkansas Department of Health (Pharmacy Services) states that persons engaged in research with controlled substances, instructional activities, chemical analysis, or animal training and animal euthanasia must obtain a Controlled Substance Registration Certificate from the State of Arkansas; clinical practitioners are not listed. ADH's March 2026 applicant memorandum describes the state registration as a registration to conduct such 'procedures' and tells applicants they must also apply to DEA. Prescribing practitioners therefore rely on their Arkansas professional license plus DEA registration.

Answer is inferred from the agency's statement of who must obtain the state certificate; the page does not expressly say 'practitioners are exempt', and Ark. Code 5-64-301 et seq. could not be opened in this session. Contact ADH Pharmacy Services (501-661-2325) to confirm.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Under the Arkansas Department of Health PDMP rules, a prescriber must check the PDMP each time prescribing a Schedule II or Schedule III opioid and the first time prescribing a benzodiazepine to a patient; licensing boards must adopt matching rules. Exemptions: controlled substances administered immediately before/during surgery, during recovery in a healthcare facility, in a healthcare facility, or in emergencies; palliative care, hospice and nursing home residents; and system failures. Oncologists must check at an initial malignant diagnosis and every three months during treatment. Otherwise PDMP use is 'encouraged' only.

Source older than 2 years - possibly stale (rule effective 12/28/2023). The PDMP TTAC list cites Ark. Code § 20-7-604 and board rules (e.g., Arkansas State Medical Board Regulation 19, AAC 060.00.1-19) for the mandate; statute text itself was not opened. Testosterone (C-III, non-opioid) is not caught.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Under 17 CAR 140-701 a physician who wants to dispense legend drugs must apply to the Arkansas State Medical Board and demonstrate the need before approval. Exempt: physicians dispensing before April 12, 2013; physicians dispensing only non-controlled injectables; and dispensing of topicals, naloxone, nicotine replacement, contraceptives, non-controlled acute-care drugs for up to 14 days, and initial non-controlled maintenance therapy (hypertension, diabetes, cholesterol) for up to 30 days. Dispensing physicians must keep records of all distributions, label drugs with patient and prescriber information, and make records available to board inspectors. Dispensing a controlled substance such as testosterone therefore needs board approval.

Rule page shows no effective date; access date used.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

Out-of-state physicians who perform patient-care acts for patients in Arkansas by electronic means are practicing medicine in Arkansas and are regulated by the Arkansas State Medical Board (Ark. Code 17-95-206). A professional relationship can be established by telemedicine that meets the in-person standard of care, but not by questionnaire, email, text or fax alone (Ark. Code 17-80-402, -403). Under the Medical Board's rule, a physician using telemedicine may not prescribe any Schedule II-V controlled substance, including testosterone, unless the physician has seen the patient in person or the relationship exists through consultation or referral. IMLC: passed, implementation delayed.

IMLC map shows Arkansas 'Passed; Implementation Delayed' (dated 3/12/2025).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Arkansas State Medical Board's delegation rule (17 CAR pt. 140, subpt. 25, proposed amendments July 2025) covers delegation to unlicensed medical assistants: drug administration may be delegated only for drugs not requiring substantial specialized judgment, only within the delegating physician's or PA's offices, and after the physician evaluates patient acuity and the assistant's competency. No Arkansas State Board of Nursing or Medical Board statement specific to RN administration of neuromodulators or fillers was located.

The fetched delegation rule is a markup of proposed amendments (draft dated 2025-07-08). Check with the Arkansas State Board of Nursing.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

An Arkansas State Board of Nursing 'APRN Corner' article (ASBN Update) says IV spa hydration facilities are not individually licensed or regulated in Arkansas, but the services are medical: they require an order or prescription from a licensed provider, including a provider-patient relationship, determination of need, documentation and record keeping. Only licensed nurses should insert the IV and administer fluids, and providers with active prescriptive authority should prescribe the fluid and additives for individual patients. It cautions that mixing products into saline may be compounding, and flags transport and storage problems for mobile services.

This is a board newsletter article, not a formal position statement or rule. Date inferred from the file name '2.4.26' (it was cited by Nebraska in Jan. 2026 as ASBN Update Edition 135); treat the date as approximate.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide classifies Arkansas as moderate, citing Ark. Code Ann. §§17-95-202 and 4-29-309(a) and Ark. Att'y Gen. Op. No. 2014-118. MedPath Compliance (reviewed 2026-06-20) lists Arkansas as a CPOM state based on statute and AG opinion.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

The Arkansas State Medical Board's rules page (checked 2026-09-23) links only the physician assistant and delegation subparts; no laser-specific rule was located. A 2024–2026 vendor blog lists physicians, RNs, PAs and electrologists under physician supervision, but that could not be verified against an official source.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Arkansas was not among them, but this research did not confirm its statutes. Arkansas's CLIA state agency is Arkansas Dept. of Health, Health Facility Services (adh.hfs@arkansas.gov, 501-661-2201); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Arkansas's rule. Arkansas's lab regulator (CLIA state agency) is Arkansas Dept. of Health, Health Facility Services (adh.hfs@arkansas.gov, 501-661-2201). The question matters for take-home and consumer test kits, not for panels a clinician orders.

A commercial 2026 guide (Just Labs) describes Arkansas as permissive, except for controlled-substance tests; not confirmed against state law. The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Arkansas is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Arkansas does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.